Characteristics of GABA release induced by free radicals in mouse hippocampal slices.
The release of the inhibitory neurotransmitter GABA is generally enhanced under potentially cell-damaging conditions. The properties and regulation of preloaded [3H]GABA release from mouse hippocampal slices were now studied in free radical-containing medium in a superfusion system. Free radical production was induced by 0.01% of H2O2 in the medium. H2O2 markedly potentiated GABA release, which was further enhanced about 1.5-fold by K+ stimulation (50 mM). In Ca2+-free media this stimulation was not altered, indicating that the release was mostly Ca2+-independent. Moreover, omission of Na+ increased the release, suggesting that it is mediated by Na+-dependent transporters operating outwards, a conception confirmed by the enhancement with GABA homoexchange. Inhibition of the release with the ion channel inhibitors diisothiocyanostilbene-2,2'-disulphonate and 4-acetamido-4'-isothiocyanostilbene-2,2'-disulphonate indicates that Cl(-) channels also participate in the process. This release was not modified by the adenosine receptor (A1 and A2a) agonists and ionotropic glutamate receptor agonists kainate, N-methy-D: -aspartate and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate, whereas the agonists of metabotropic glutamate receptors of group I [(S)-3,5-dihydroxyphenylglycine] and of group II [(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate] enhanced it by receptor-mediated mechanisms, the effects being abolished by their respective antagonists. The group III agonist L+-2-amino-4-phosphonobutyrate reduced the evoked GABA release, but this was not affected by the antagonist. Furthermore, the release was reduced by activation of protein kinase C by 4 beta-phorbol 12-myristate 13-acetate and by inhibition of tyrosine kinase by genistein and of phoshoplipase by quinacrine. On the other hand, increasing cGMP levels with the phosphodiesterase inhibitor zaprinast, selective for PDE5, 6 and 9, and NO production with the NO-generating compounds hydroxylamine, sodium nitroprusside and S-nitroso-N-penicillamine enhanced the release. The regulation of GABA release induced by free radical production proved thus to be rather complex. Under potentially cell-damaging conditions, the potentiation of GABA release may be a mechanism to counteract hyperactivity and reduce the effects of excitatory amino acid release. On the other hand, reduction of GABA release could be harmful and contribute to excitotoxic damage and neuronal degeneration.
Saransaari
Pirjo
P
Tampere Brain Research Center, Medical School, University of Tampere, Tampere 33014, Finland. blpisa@uta.fi
Oja
Simo S
SS
D058907:Adenosine A1 Receptor Agonists; D058908:Adenosine A2 Receptor Agonists; D000818:Animals; D002118:Calcium / Q000378:metabolism; D018118:Chloride Channels / Q000187:drug effects / Q000378:metabolism; D002712:Chlorides / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D005609:Free Radicals / Q000494:pharmacology*; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism*; D006861:Hydrogen Peroxide / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D051379:Mice; D011493:Protein Kinase C / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D017470:Receptors, Glutamate / Q000187:drug effects; D015290:Second Messenger Systems; D012964:Sodium / Q000378:metabolism; D026941:Sodium Channel Blockers / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D058907:Adenosine A1 Receptor Agonists; D058908:Adenosine A2 Receptor Agonists; D018118:Chloride Channels; D002712:Chlorides; D005609:Free Radicals; D018755:GABA Agonists; D018756:GABA Antagonists; D017470:Receptors, Glutamate; D026941:Sodium Channel Blockers; D005680:gamma-Aminobutyric Acid; D012964:Sodium; D006861:Hydrogen Peroxide; D011505:Protein-Tyrosine Kinases; D011493:Protein Kinase C; D002118:Calcium
Prog Neurobiol. 1998 Apr;54(5):581-618
9550192
J Neurochem. 1996 May;66(5):2057-66
8780036
Brain Res. 1999 Oct 9;844(1-2):1-9
10536255
Brain Res. 1983 Dec 19;289(1-2):197-204
6318894
Brain Res Mol Brain Res. 2001 Apr 18;89(1-2):111-8
11311981
Eur J Neurosci. 1995 Sep 1;7(9):1906-13
8528465
Annu Rev Neurosci. 1994;17:153-83
7516125
Mol Pharmacol. 1990 Apr;37(4):477-81
1970115
Neurochem Int. 2003 Sep-Oct;43(4-5):453-9
12742091
Eur J Neurosci. 1997 Mar;9(3):472-9
9104589
Trends Neurosci. 1996 Jul;19(7):267-71
8799968
Neurosci Lett. 1984 May 4;46(2):137-43
6330619
Neurochem Res. 2006 Nov;31(11):1317-25
17053971
Comp Biochem Physiol A Comp Physiol. 1991;99(3):263-77
1678326
Int J Dev Neurosci. 1997 Apr;15(2):163-74
9178035
Brain Res. 1987 Dec 15;465(1-2):277-91
3440208
Dev Neurosci. 1983-1984;6(4-5):271-7
6680690
J Neurochem. 1992 Nov;59(5):1609-23
1402908
Neurosci Lett. 1992 May 11;139(1):77-82
1407685
J Neurochem. 1995 Sep;65(3):1109-14
7643088
Biochemistry. 1988 Jan 12;27(1):12-7
3349023
J Neurochem. 1988 Apr;50(4):1322-4
2894412
Prog Neurobiol. 1993 Jun;40(6):645-70
8484006
Neurochem Res. 1993 Apr;18(4):445-52
8097294
Trends Pharmacol Sci. 1988 Apr;9(4):130-4
2907698
J Neurochem. 2000 Sep;75(3):889-907
10936169
Neurosci Lett. 1995 Nov 17;200(2):101-4
8614554
Amino Acids. 2006 Jul;31(1):35-43
16680399
Brain Res. 1989 Apr 3;483(2):384-8
2706529
J Neurosci Res. 1989 Nov;24(3):437-44
2593184
Proc Natl Acad Sci U S A. 1989 Jul;86(13):5159-62
2567995
Prog Neurobiol. 1999 Sep;59(1):55-79
10416961
Amino Acids. 2004 Feb;26(1):91-8
14752622
Cardiovasc Res. 1989 Sep;23(9):767-73
2611815
J Membr Biol. 1998 Jul 1;164(1):1-10
9636239
Brain Res. 1993 Apr 23;609(1-2):117-23
8389646
Neurochem Res. 2001 Feb;26(2):175-80
11478745
Neurochem Res. 2004 Aug;29(8):1511-8
15260128
Brain Res. 1998 Jan 26;782(1-2):290-6
9519275
J Biol Chem. 1992 Sep 5;267(25):17491-3
1517200
Eur J Pharmacol. 1997 Feb 26;321(2):247-57
9063695
Brain Res. 1993 Apr 9;608(1):27-32
8495345
Cell Mol Neurobiol. 1998 Dec;18(6):667-82
9876873
Eur J Neurosci. 1995 Dec 1;7(12):2518-23
8845958
Trends Neurosci. 1994 Sep;17(9):359-65
7529438
Br J Pharmacol. 1996 Oct;119(3):590-4
8894183
Prog Neurobiol. 1991;36(4):329-41
1678539
Proc Soc Exp Biol Med. 1995 Apr;208(4):337-45
7700883
J Neurosci Methods. 1995 Jun;59(1):93-8
7475256
Pflugers Arch. 2002 Oct;445(1):87-96
12397392
Neurosci Lett. 1995 Feb 13;185(3):191-4
7753489
Prog Neurobiol. 1992;38(5):455-82
1589578
Neurochem Res. 1997 Mar;22(3):273-80
9051661
Free Radic Biol Med. 1989;6(5):485-92
2744581
Neurochem Res. 1999 Aug;24(8):1009-16
10478940
Neurochem Res. 2005 Dec;30(12):1549-56
16362774
Neuroscience. 1988 Nov;27(2):373-85
3216999
Neurochem Res. 2005 Apr;30(4):467-73
16076017
Neurochem Res. 1998 Apr;23 (4):563-70
9566593
Neurochem Res. 1988 Oct;13(10):923-8
3216949
J Neurochem. 1994 May;62(5):1757-63
8158126
Prog Neurobiol. 1998 Aug;55(5):463-75
9670214
Neurochem Int. 2003 Sep-Oct;43(4-5):461-7
12742092
Biochem Pharmacol. 1993 Aug 3;46(3):525-34
8394084
Neuropharmacology. 1995 Aug;34(8):1081-7
8532157
Neuron. 2000 Mar;25(3):663-72
10774733